drugset

drugset / Trial / NCT04670055

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

NCT04670055 ↗

Phase 0 Not yet recruiting 50 enrolled Zhejiang University Yake Biotechnology Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

Timeline

Start: 2021-01-01
Primary completion: 2024-01-01
Completion: 2027-01-01

Publications

Chen R, Jin C, Liu K, Zhao M, Yang T, Zhang M, Xiao P, Feng J, Hong R, Fu S, Cui J, Huang S, Wei G, Huang H, Hu Y. Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells. Chin Med J (Engl). 2025 Oct 5;138(19):2481-2490. doi: 10.1097/CM9.0000000000003306. Epub 2024 Nov 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BCMA Targeted CAR T-cells	Cell therapy	—	Intravenous

Indications